The Efficacy of Rebamipide or Ecabet Sodium Supplementation for Helicobacter pylori Eradication Therapy Compared with Quadruple (Concomitant) Regimen.
10.4166/kjg.2018.71.4.204
- Author:
Joonhwan KIM
1
;
Kyungwon KIM
;
Jun Soo LEE
;
Su Young KIM
;
Kyung Oh KIM
;
Yoon Jae KIM
;
Kwang an KWON
;
Dong Kyun PARK
;
Jun Won CHUNG
Author Information
1. Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea. junwonchung@daum.net
- Publication Type:Original Article
- Keywords:
Helicobacter pylori;
Therapeutics;
Rebamipide;
Ecabet sodium
- MeSH:
Amoxicillin;
Clarithromycin;
Compliance;
Helicobacter pylori*;
Helicobacter*;
Humans;
Lansoprazole;
Medical Records;
Metronidazole;
Multivariate Analysis;
Retrospective Studies;
Sodium*
- From:The Korean Journal of Gastroenterology
2018;71(4):204-212
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Although some previous studies reported that a treatment combined with mucoprotective agent could improve the eradication rate in dual or triple therapy, there are other reports that question the efficacy of combining these drugs in concomitant therapy (CoCTx). The aim of this study was to investigate the effects of rebamipide or ecabet on the Helicobacter pylori (H. pylori) eradication combined with CoCTx. METHODS: We retrospectively reviewed the medical records of 277 patients with proven H. pylori infection. They were assigned to one of 3 regimens for 10 days, twice daily: (a) CoCTx (n=118): lansoprazole 30 mg, amoxicillin 1 g, metronidazole 500 mg, and clarithromycin 500 mg; (b) CoCTx+rebamipide (100 mg) (n=85); (c) CoCTx+ecabet (1 g) (n=74). RESULTS: The baseline characteristics were not significantly different. H. pylori eradication rates were 82.2% (97/118) in CoCTx, 90.6% (77/85) in CoCTx+rebamipide, and 89.2% (66/74) in CoCTx+ecabet (p=0.17), which were statistically insignificant. Overall adverse events were more frequently reported in the CoCTx+rebamipide (50.6%. 43/85) and CoCTx+ecabet (44.6%, 33/74) groups than in the CoCTx (32.2%, 38/118) (p = 0.03) group. Drug compliances were not different between three groups (CoCTx: 95.8%, 113/118; CoCT+rebamipide: 92.9%, 79/85; CoCTx+ecabet 98.6%,73/74) (p=0.209). Multivariate analysis showed that the risk of eradication failure was significantly increased with decreased drug compliance (odds ratio 3.52, 95% confidence interval 1.00–12.32; p=0.05). CONCLUSIONS: Addition of these mucoprotective agent was not superior to CoCTx alone for eradicating H. pylori infection with frequent adverse events. Rather, drug compliance is the most related factor affecting the eradication rate. Our data suggest the importance of drug compliance over the drugs used.
